Contact UsCompany ProfileHome
Saaskin Technologies
Send Inquiry Send SMS
Snibe MAGLUMI CK-MB (CLIA) Snibe MAGLUMI CK-MB (CLIA) Snibe MAGLUMI CK-MB (CLIA)
Snibe MAGLUMI CK-MB (CLIA)
Snibe MAGLUMI CK-MB (CLIA) Snibe MAGLUMI CK-MB (CLIA)

Snibe MAGLUMI CK-MB (CLIA)

Get a Price/Quote

Product Details:

  • Storage Instructions Store at 2-8C
  • Shelf Life 12 months
  • Measurement Range 0.3150 ng/mL
  • Accuracy CV 10%
  • Function CK-MB quantitative analysis
  • Features High sensitivity, specific detection, rapid turnaround time
  • Usage Type Hospital, Clinical Laboratory
  • Click to View more
Request to Call Back Send Inquiry
X

Snibe MAGLUMI CK-MB (CLIA) Price And Quantity

  • High, no cross reactivity reported
  • 0.3 ng/mL
  • Within 30 minutes
  • CE-IVD certified
  • Sealed cartridges for automated processing
  • Detection and monitoring of myocardial infarction (MI)
  • Yes, provided
  • 50 L per test
  • Recommended with each new reagent lot

Snibe MAGLUMI CK-MB (CLIA) Product Specifications

  • Compatible with Snibe MAGLUMI Series Analyzers
  • No
  • High sensitivity, specific detection, rapid turnaround time
  • Hospital, Clinical Laboratory
  • Diagnostic reagents, plastic cartridges
  • White/Blue
  • Yes (kit form)
  • CK-MB quantitative analysis
  • Chemiluminescence Immunoassay (CLIA)
  • New
  • Yes
  • Quantitative determination of CK-MB in human serum or plasma
  • 0.3150 ng/mL
  • Automated
  • CV 10%
  • Store at 2-8C
  • Not applicable (kit format)
  • 12 months
  • In-Vitro Diagnostic Reagent Kit
  • High, no cross reactivity reported
  • 0.3 ng/mL
  • Within 30 minutes
  • CE-IVD certified
  • Sealed cartridges for automated processing
  • Detection and monitoring of myocardial infarction (MI)
  • Yes, provided
  • 50 L per test
  • Recommended with each new reagent lot

Product Description

Brand Snibe
Sample Type Serum
Pack Size 100T
CAT No. 130206001M
Application Cardiac Marker

The kit has been designed for the quantitative determination of the MB isoenzyme of creatine kinase (CK-MB) in human serum. The method can be used for samples over the range of 0-300 ng/ml. The test has to be performed on the MAGLUMI chemiluminescence immunoassay (CLIA) fully auto analyzer (Including MAGLUMI 1000, MAGLUMI 2000, MAGLUMI 2000 Plus and new developed models).



Rapid and Reliable Myocardial Infarction Detection

The MAGLUMI CK-MB kit empowers healthcare professionals to quickly and accurately assess myocardial infarction risk. Its robust CLIA technology provides specific detection of CK-MB in serum or plasma, minimizing waiting periods with results ready in under 30 minutes. Compatible automation ensures ease of use in busy laboratory settings.


Advanced Performance with High Sensitivity and Specificity

Delivering a sensitivity of 0.3 ng/mL and meticulous lot traceability, this CE-IVD certified kit assures clinicians of both accuracy and reliability. The absence of cross-reactivity further enhances confidence in CK-MB measurements, supporting sound clinical decisions for cardiac patient management.


User-Friendly Design and Practical Usage

Sealed, color-coded cartridges simplify the testing workflow, reducing manual handling and error risk. Calibration with each reagent lot ensures consistent results. The kit's compact format and storage at 2-8C suit a range of healthcare environments, including hospitals and clinical laboratories throughout India.

FAQ's of Snibe MAGLUMI CK-MB (CLIA):


Q: How does the Snibe MAGLUMI CK-MB (CLIA) kit function for myocardial infarction monitoring?

A: The kit quantitatively measures CK-MB levels in human serum or plasma using chemiluminescence immunoassay (CLIA) technology, aiding in both the detection and monitoring of myocardial infarction (MI) within a rapid 30-minute timeframe.

Q: What are the steps involved in using the CK-MB kit with Snibe MAGLUMI analyzers?

A: To use the kit, load the patient sample (50 L) into the analyzer using the sealed, automated cartridges. Calibration is needed with each new reagent lot, after which the analyzer processes and reports results in under 30 minutes.

Q: When should recalibration of the Snibe MAGLUMI CK-MB kit be performed?

A: Recalibration is recommended whenever a new reagent lot is introduced to ensure optimal accuracy and consistency in CK-MB measurement.

Q: Where can the Snibe MAGLUMI CK-MB (CLIA) kit be used effectively?

A: Its portable kit format and compatibility with automated analyzers make it suitable for hospitals and clinical laboratories, especially for facilities in need of rapid cardiac biomarker evaluation.

Q: What is the measurement range and accuracy of this CK-MB assay?

A: The kit offers a measurement range of 0.3-150 ng/mL with an accuracy expressed as a coefficient of variation (CV) of 10%, ensuring dependable performance.

Q: How does using this kit benefit clinical decision-making for cardiac patients?

A: Its high sensitivity, rapid result turnaround, and minimal cross-reactivity allow clinicians to make timely and confident decisions regarding the management of myocardial infarction cases.

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

Other Products in 'Medical CLIA' category

Snibe MAGLUMI CA 19-9 (CLIA)
Send Inquiry
Snibe MAGLUMI Aldosterone (CLIA)
Send Inquiry
MAGLUMI Serum Amyloid A (CLIA)
Send Inquiry
MAGLUMI SARS-CoV-2 Neutralizing Antibody (CLIA)
Send Inquiry
SEND INQUIRY CALL ME FREE


  • Saaskin Corporation Private Limited.
    GST : 33AAZCS6003M1ZU
  • 275/184, 1st Floor, Office No: 2, Golden Enclave, Periyar E V R Salai, P.H. Road, Kilpauk,Chennai - 600010, Tamil Nadu, India
  • Mobile : 0091 9840819191 / 9940116677
  • Phone:07971189171
  • Mr Rajesh H (Business Operations Manager)
  • Mobile:07971189171
  • Send Inquiryinfo@saaskin.com
    send inqSend Inquiry
    Send SMS
trade india member
SAASKIN CORPORATION PRIVATE LIMITED All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.